Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera

• Status: Recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality owing to progression of a high percentage (85%) of HCV infected patients to chronic hepatitis, which might lead to the development of liver cirrhosis or hepato cellular carcinoma..

Egypt has possibly the highest HCV prevalence in the world, 10-20% of the general population .

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Mitogens; Sofosbuvir

Criteria

Inclusion Criteria:

• Age from 18 to 70 years.

• HCV RNA positivity .

• Any Body Mass Index(BMI).

• Treatment-naive or treatment experienced.

• all fibrosis stages.

Exclusion criteria:

• Direct serum bilirubin greater than 2 mg/dl.

• Serum albumin less than 2.8 g/dl.

• International normalization ratio (INR) greater than or equal to 1.7

• Platelet count less than 50 000/mm3.

• Ascites or history of ascites.

• Hepatic encephalopathy or history of hepatic encephalopathy.

• Hepatocellular carcinoma.

• Serum creatinine greater than 2.5 mg/dl .

• Pregnancy.